Charles River Laboratories CRL Redeemable NCI
Redeemable NCI at other companies
Other financials
Where this comes from
Reported directly by Charles River Laboratories in its filing.
Tagged under the XBRL concept us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount.
The official record: Charles River Laboratories’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Charles River Laboratories's redeemable nci.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Charles River Laboratories's redeemable NCI?
- Charles River Laboratories (CRL) reported redeemable NCI of $41.9M in Q1 2026.
- How has Charles River Laboratories's redeemable NCI changed year-over-year?
- Charles River Laboratories's redeemable NCI increased by 0.6% year-over-year, from $41.66M to $41.9M.
- What is the long-term trend for Charles River Laboratories's redeemable NCI?
- Over 5 years (2020 to 2025), Charles River Laboratories's redeemable NCI has grown at a 10.1% compound annual growth rate (CAGR), from $25.5M to $41.26M.
- What does redeemable NCI mean?
- Ownership stakes held by others in a subsidiary that the company may be required to buy back.
- How do you interpret redeemable NCI?
- An increase indicates higher potential future cash obligations, which could impact liquidity.
- How does redeemable NCI compare across companies?
- Common in companies with complex joint ventures or acquisition-heavy growth strategies.